Genmab — December 2018
-
Der skal cost-benefit beregninger til. Hvad koster det på den længere bane, at undlade den bedste behandling fra starten ?
-
Vi kan ikke afvise at der er analytikere som har regnet forkert og skal have efterset deres beregninger. Men som jeg har forstaaet er det en fordel at angribe sygdommen MM massivt og i starten af sygdomsforloebet saa derfor tror jeg darzalex bliver 1st valg sammen med andre
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind